NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer

Figure 2 Knockdown of NOTCH1 enhances the chemosensitivity of triple-negative breast cancer cells to cisplatin. A: Analysis of cell sensitivity to cisplatin showing that, compared to control cells (IC₅₀ = 15.36 μM), stable NOTCH1-knockdown MDA-MB-231 cells exhibited higher sensitivity to cisplatin treatment (IC₅₀ = 10.20 μM); B: CCK-8 assay indicating that the combination of NOTCH1 knockdown and cisplatin treatment significantly inhibited cell proliferation; C: TUNEL assay showing that after NOTCH1 knockdown and cisplatin treatment, the proportion of apoptotic cells significantly increases. ^aP < 0.05; ^bP < 0.01.